ログイン

LADMER

LADMER
50問 • 1年前
  • Quinn Karylle Fuentes
  • 通報

    問題一覧

  • 1

    The study of the chemical and physical properties of drugs, their components, and their activities in living organisms.

    Biopharmaceuticals.

  • 2

    The science that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption.

    Biopharmaceuticals

  • 3

    measurement of the rate and extent of systemic absorption of therapeutically active drug

    Bioavailability

  • 4

    The study of the time course of drug movement in the body during absorption, distribution, and elimination.

    Pharmacokinetics.

  • 5

    The study of the relationships between drug dosage regimens and concentration–time profiles

    Clinical pharmacokinetics.

  • 6

    Application of pharmacokinetic methods to drug therapy.

    Clinical pharmacokinetics

  • 7

    volume of fluid completely cleared of drug per unit time

    Clearance.

  • 8

    distributed to produce the measured concentration

    Volume of distribution

  • 9

    time taken for 50% of the drug to be eliminated

    Elimination half life

  • 10

    Study of pharmacokinetics differences of drugs in various population

    Population pharmacokinetics

  • 11

    Employed for very potent drug to optimize efficacy and to prevent any adverse toxicity

    Therapeutic drug monitoring.

  • 12

    Provides pharmacokinetic and drug analysis services for safe drug monitoring

    Clinical pharmacokinetics service.

  • 13

    Development of biologic sampling techniques, analytical methods for the measurement of drugs and metabolites and procedure that facilitates data collection and manipulation

    Expirinental pharmacokinetics.

  • 14

    Development of pharmacokinetics models that predict drug disposition after administration

    Theoretical pharmacokinetics.

  • 15

    involves human subjects/ laboratory animals

    In VIVO

  • 16

    employs test apparatus and equipment without involving human subjects/ laboratory animals

    in VITRO

  • 17

    hypothesis using mathematical terms to describe quantitative relationship concisely.

    Model

  • 18

    The study of the relation of the drug concentration or amount at the site of action and its pharmacologic response

    Pharmacodynamic

  • 19

    The study of the adverse effects of drugs and toxic substances in the body

    Clinical toxicology.

  • 20

    description of drug distribution and elimination

    Drug disposition

  • 21

    refers to the dose and various measure of acute or integrated drug concentrations in plasma and other biological fluid

    Drug exposure.

  • 22

    refers to the direct measure of the pharmacologic effect of the drug

    Drug response.

  • 23

    The rate at which the solid drug enters into solution is often the rate limiting step in bioavailability.

    Drug dissolution.

  • 24

    What equation describes the diffusion controlled rate of drug dissolution

    Noyes-Whitney equation

  • 25

    in a saturated solution is a static (equilibrium) property. The dissolution rate of a drug is a dynamic property related to the rate of absorption.

    Drug solubility

  • 26

    The partition coefficient of a drug is the ratio of the solubility of the drug, at equilibrium, in a non-aqueous solvent

    Partition coefficient

  • 27

    Drugs that are weak electrolytes (acids or bases) exist in both an ionized form and a nonionized form in solution

    Extent of ionization

  • 28

    The extent of ionization depends on the pKa of the weak electrolyte and the pH of the solution (£T/F)

    True

  • 29

    This equation describes the relation between the ionized and the nonionized forms of a drug as a function of pH and pKa

    Henderson-Hasselbalch equation

  • 30

    The choice of salt form for a drug depends on the desired physical , chemical , or pharmacologic properties.

    Salt formation.

  • 31

    the ability of a drug to exist in more than one crystalline form Amorphous, or noncrystalline, forms of a drug have faster dissolution rates than do crystalline forms.

    Polymorphism.

  • 32

    The ability of a drug to exist as optically active stereoisomers or enantiomers

    Chirality

  • 33

    Individual enantiomers may not have the same pharmacokinetic and pharmacodynamic activity.

    Chirality.

  • 34

    Drugs may exist in a hydrated, or solvated, form or as an anhydrous molecule Dissolution rates differ for hydrated and anhydrous forms.

    Hydrates

  • 35

    Decrease water solubility

    Hydrates

  • 36

    formed by the reversible or irreversible association of two or more interacting molecules or ions.

    Complex formation.

  • 37

    are complexes that typically involve a ring-like structure formed by the interaction between a partial ring of atoms and a metal Ex. hemoglobin, insulin, cyanocobalamin

    Chelates

  • 38

    Complex formation usually alters the physical and chemical characteristics of the drug

    Chelates

  • 39

    the process with the slowest rate constant in a system of simultaneous kinetic processes.

    Rate limiting step

  • 40

    delivery of the active ingredient from a dosage form into solution.

    Liberation

  • 41

    the first step which determines onset of action, rate of absorption, availability, etc., which is true for all drug products by all routes of administration

    Liberation

  • 42

    The process of uptake of the compound from the site of administration into the systemic circulation.

    Absorption

  • 43

    The movement of the drug from the site of application to the bloodstream.

    Absorption

  • 44

    transfer of the drug from the blood to extravascular fluids and tissues

    Distribution

  • 45

    The amount of blood perfusion in an area of the body also affects the rate at which the drug could be distributed there.

    Distribution

  • 46

    Estimate the extent of drug distribution in the body

    Volume of distribution

  • 47

    Relates the plasma conc to the amount of drug

    Volume of distribution

  • 48

    Detoxification/Biotransformation enzymatic or biochemical transformation of the drug substance to (usually less toxic) metabolic products, which may be eliminated more readily from the body

    Metabolism

  • 49

    final loss of the drug substance or its metabolites from the body

    Excretion.

  • 50

    Make the drug MORE POLAR

    Metabolism

  • Cell structure.

    Cell structure.

    Quinn Karylle Fuentes · 28問 · 2年前

    Cell structure.

    Cell structure.

    28問 • 2年前
    Quinn Karylle Fuentes

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    Quinn Karylle Fuentes · 29問 · 2年前

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    29問 • 2年前
    Quinn Karylle Fuentes

    MW

    MW

    Quinn Karylle Fuentes · 45問 · 2年前

    MW

    MW

    45問 • 2年前
    Quinn Karylle Fuentes

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    Quinn Karylle Fuentes · 38問 · 2年前

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    38問 • 2年前
    Quinn Karylle Fuentes

    Density and specific gravity

    Density and specific gravity

    Quinn Karylle Fuentes · 34問 · 2年前

    Density and specific gravity

    Density and specific gravity

    34問 • 2年前
    Quinn Karylle Fuentes

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    Quinn Karylle Fuentes · 18問 · 2年前

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    18問 • 2年前
    Quinn Karylle Fuentes

    Microbial growth

    Microbial growth

    Quinn Karylle Fuentes · 63問 · 2年前

    Microbial growth

    Microbial growth

    63問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 61問 · 2年前

    Introduction.

    Introduction.

    61問 • 2年前
    Quinn Karylle Fuentes

    Microbial control.

    Microbial control.

    Quinn Karylle Fuentes · 97問 · 2年前

    Microbial control.

    Microbial control.

    97問 • 2年前
    Quinn Karylle Fuentes

    States of matter

    States of matter

    Quinn Karylle Fuentes · 100問 · 2年前

    States of matter

    States of matter

    100問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 86問 · 2年前

    Introduction.

    Introduction.

    86問 • 2年前
    Quinn Karylle Fuentes

    Drug development.

    Drug development.

    Quinn Karylle Fuentes · 77問 · 2年前

    Drug development.

    Drug development.

    77問 • 2年前
    Quinn Karylle Fuentes

    CGMP

    CGMP

    Quinn Karylle Fuentes · 9問 · 2年前

    CGMP

    CGMP

    9問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    Quinn Karylle Fuentes · 24問 · 2年前

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    24問 • 2年前
    Quinn Karylle Fuentes

    Powdered & granules

    Powdered & granules

    Quinn Karylle Fuentes · 43問 · 2年前

    Powdered & granules

    Powdered & granules

    43問 • 2年前
    Quinn Karylle Fuentes

    Capsule.

    Capsule.

    Quinn Karylle Fuentes · 24問 · 2年前

    Capsule.

    Capsule.

    24問 • 2年前
    Quinn Karylle Fuentes

    Tablets.

    Tablets.

    Quinn Karylle Fuentes · 23問 · 2年前

    Tablets.

    Tablets.

    23問 • 2年前
    Quinn Karylle Fuentes

    Calculatiom of dose

    Calculatiom of dose

    Quinn Karylle Fuentes · 3回閲覧 · 66問 · 2年前

    Calculatiom of dose

    Calculatiom of dose

    3回閲覧 • 66問 • 2年前
    Quinn Karylle Fuentes

    Postlab 5&6

    Postlab 5&6

    Quinn Karylle Fuentes · 29問 · 2年前

    Postlab 5&6

    Postlab 5&6

    29問 • 2年前
    Quinn Karylle Fuentes

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    Quinn Karylle Fuentes · 33問 · 2年前

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    33問 • 2年前
    Quinn Karylle Fuentes

    SEMI SOLID

    SEMI SOLID

    Quinn Karylle Fuentes · 69問 · 2年前

    SEMI SOLID

    SEMI SOLID

    69問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology

    Basic immunology

    Quinn Karylle Fuentes · 60問 · 2年前

    Basic immunology

    Basic immunology

    60問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology (2)

    Basic immunology (2)

    Quinn Karylle Fuentes · 62問 · 2年前

    Basic immunology (2)

    Basic immunology (2)

    62問 • 2年前
    Quinn Karylle Fuentes

    Transdermal

    Transdermal

    Quinn Karylle Fuentes · 44問 · 2年前

    Transdermal

    Transdermal

    44問 • 2年前
    Quinn Karylle Fuentes

    Distribution.

    Distribution.

    Quinn Karylle Fuentes · 43問 · 2年前

    Distribution.

    Distribution.

    43問 • 2年前
    Quinn Karylle Fuentes

    Infectious disease.

    Infectious disease.

    Quinn Karylle Fuentes · 65問 · 2年前

    Infectious disease.

    Infectious disease.

    65問 • 2年前
    Quinn Karylle Fuentes

    Infectious diseases (2)

    Infectious diseases (2)

    Quinn Karylle Fuentes · 79問 · 2年前

    Infectious diseases (2)

    Infectious diseases (2)

    79問 • 2年前
    Quinn Karylle Fuentes

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    Quinn Karylle Fuentes · 35問 · 2年前

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    Quinn Karylle Fuentes · 35問 · 2年前

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic ( Compressed)

    All topic ( Compressed)

    Quinn Karylle Fuentes · 30問 · 2年前

    All topic ( Compressed)

    All topic ( Compressed)

    30問 • 2年前
    Quinn Karylle Fuentes

    All topics (compressed)

    All topics (compressed)

    Quinn Karylle Fuentes · 13問 · 2年前

    All topics (compressed)

    All topics (compressed)

    13問 • 2年前
    Quinn Karylle Fuentes

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    Quinn Karylle Fuentes · 28問 · 2年前

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    28問 • 2年前
    Quinn Karylle Fuentes

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    Quinn Karylle Fuentes · 16問 · 2年前

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    16問 • 2年前
    Quinn Karylle Fuentes

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    Quinn Karylle Fuentes · 26問 · 2年前

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    26問 • 2年前
    Quinn Karylle Fuentes

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    Quinn Karylle Fuentes · 23問 · 2年前

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    23問 • 2年前
    Quinn Karylle Fuentes

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Quinn Karylle Fuentes · 35問 · 2年前

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    35問 • 2年前
    Quinn Karylle Fuentes

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    Quinn Karylle Fuentes · 20問 · 2年前

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    20問 • 2年前
    Quinn Karylle Fuentes

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    Quinn Karylle Fuentes · 33問 · 2年前

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    33問 • 2年前
    Quinn Karylle Fuentes

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    Quinn Karylle Fuentes · 37問 · 2年前

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    37問 • 2年前
    Quinn Karylle Fuentes

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    Quinn Karylle Fuentes · 23問 · 2年前

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    23問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae

    Enterobacteriaceae

    Quinn Karylle Fuentes · 35問 · 2年前

    Enterobacteriaceae

    Enterobacteriaceae

    35問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae.

    Enterobacteriaceae.

    Quinn Karylle Fuentes · 28問 · 2年前

    Enterobacteriaceae.

    Enterobacteriaceae.

    28問 • 2年前
    Quinn Karylle Fuentes

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    Quinn Karylle Fuentes · 31問 · 2年前

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    31問 • 2年前
    Quinn Karylle Fuentes

    Liquid dosage form

    Liquid dosage form

    Quinn Karylle Fuentes · 12問 · 2年前

    Liquid dosage form

    Liquid dosage form

    12問 • 2年前
    Quinn Karylle Fuentes

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    Quinn Karylle Fuentes · 44問 · 2年前

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    44問 • 2年前
    Quinn Karylle Fuentes

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    Quinn Karylle Fuentes · 22問 · 2年前

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    22問 • 2年前
    Quinn Karylle Fuentes

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    Quinn Karylle Fuentes · 40問 · 2年前

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    40問 • 2年前
    Quinn Karylle Fuentes

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    Quinn Karylle Fuentes · 29問 · 2年前

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    29問 • 2年前
    Quinn Karylle Fuentes

    Drug incompatibilities.

    Drug incompatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug incompatibilities.

    Drug incompatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    Drug compatibilities.

    Drug compatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug compatibilities.

    Drug compatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 35問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    35問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 30問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    30問 • 2年前
    Quinn Karylle Fuentes

    SUSPENSION.

    SUSPENSION.

    Quinn Karylle Fuentes · 45問 · 2年前

    SUSPENSION.

    SUSPENSION.

    45問 • 2年前
    Quinn Karylle Fuentes

    Colloidal.

    Colloidal.

    Quinn Karylle Fuentes · 40問 · 2年前

    Colloidal.

    Colloidal.

    40問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    Quinn Karylle Fuentes · 38問 · 2年前

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    38問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY.

    BACTERIOLOGY.

    Quinn Karylle Fuentes · 44問 · 2年前

    BACTERIOLOGY.

    BACTERIOLOGY.

    44問 • 2年前
    Quinn Karylle Fuentes

    Emulsion.

    Emulsion.

    Quinn Karylle Fuentes · 32問 · 2年前

    Emulsion.

    Emulsion.

    32問 • 2年前
    Quinn Karylle Fuentes

    EMULSION

    EMULSION

    Quinn Karylle Fuentes · 42問 · 2年前

    EMULSION

    EMULSION

    42問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    Quinn Karylle Fuentes · 36問 · 2年前

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    36問 • 2年前
    Quinn Karylle Fuentes

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    Quinn Karylle Fuentes · 33問 · 2年前

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    33問 • 2年前
    Quinn Karylle Fuentes

    Mycology.

    Mycology.

    Quinn Karylle Fuentes · 30問 · 2年前

    Mycology.

    Mycology.

    30問 • 2年前
    Quinn Karylle Fuentes

    Mycology 2.0

    Mycology 2.0

    Quinn Karylle Fuentes · 34問 · 2年前

    Mycology 2.0

    Mycology 2.0

    34問 • 2年前
    Quinn Karylle Fuentes

    m

    m

    Quinn Karylle Fuentes · 15問 · 2年前

    m

    m

    15問 • 2年前
    Quinn Karylle Fuentes

    ppr

    ppr

    Quinn Karylle Fuentes · 25問 · 2年前

    ppr

    ppr

    25問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    Quinn Karylle Fuentes · 20問 · 2年前

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    20問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    Quinn Karylle Fuentes · 86問 · 2年前

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    86問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    Quinn Karylle Fuentes · 100問 · 2年前

    Pharmacokinetics (1.1)

    Pharmacokinetics (1.1)

    100問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    Quinn Karylle Fuentes · 19問 · 2年前

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    19問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 17問 · 2年前

    Introduction.

    Introduction.

    17問 • 2年前
    Quinn Karylle Fuentes

    Introduction of biochemistry

    Introduction of biochemistry

    Quinn Karylle Fuentes · 76問 · 2年前

    Introduction of biochemistry

    Introduction of biochemistry

    76問 • 2年前
    Quinn Karylle Fuentes

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    Quinn Karylle Fuentes · 56問 · 2年前

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    56問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 75問 · 2年前

    Carbohydrates

    Carbohydrates

    75問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates 1.1

    Carbohydrates 1.1

    Quinn Karylle Fuentes · 31問 · 2年前

    Carbohydrates 1.1

    Carbohydrates 1.1

    31問 • 2年前
    Quinn Karylle Fuentes

    Detect and quality variation.

    Detect and quality variation.

    Quinn Karylle Fuentes · 56問 · 2年前

    Detect and quality variation.

    Detect and quality variation.

    56問 • 2年前
    Quinn Karylle Fuentes

    INTRODUCTION

    INTRODUCTION

    Quinn Karylle Fuentes · 98問 · 2年前

    INTRODUCTION

    INTRODUCTION

    98問 • 2年前
    Quinn Karylle Fuentes

    lab (1-2)

    lab (1-2)

    Quinn Karylle Fuentes · 15問 · 2年前

    lab (1-2)

    lab (1-2)

    15問 • 2年前
    Quinn Karylle Fuentes

    lab 1-2

    lab 1-2

    Quinn Karylle Fuentes · 14問 · 2年前

    lab 1-2

    lab 1-2

    14問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    Quinn Karylle Fuentes · 45問 · 2年前

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    45問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    Quinn Karylle Fuentes · 35問 · 2年前

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    35問 • 2年前
    Quinn Karylle Fuentes

    Unit 3.

    Unit 3.

    Quinn Karylle Fuentes · 39問 · 2年前

    Unit 3.

    Unit 3.

    39問 • 2年前
    Quinn Karylle Fuentes

    Histamin and kinins

    Histamin and kinins

    Quinn Karylle Fuentes · 70問 · 2年前

    Histamin and kinins

    Histamin and kinins

    70問 • 2年前
    Quinn Karylle Fuentes

    PUD.

    PUD.

    Quinn Karylle Fuentes · 45問 · 2年前

    PUD.

    PUD.

    45問 • 2年前
    Quinn Karylle Fuentes

    ..

    ..

    Quinn Karylle Fuentes · 61問 · 2年前

    ..

    ..

    61問 • 2年前
    Quinn Karylle Fuentes

    Lipids.

    Lipids.

    Quinn Karylle Fuentes · 67問 · 2年前

    Lipids.

    Lipids.

    67問 • 2年前
    Quinn Karylle Fuentes

    lipids.

    lipids.

    Quinn Karylle Fuentes · 71問 · 2年前

    lipids.

    lipids.

    71問 • 2年前
    Quinn Karylle Fuentes

    LAB ✨

    LAB ✨

    Quinn Karylle Fuentes · 93問 · 2年前

    LAB ✨

    LAB ✨

    93問 • 2年前
    Quinn Karylle Fuentes

    Drug discovery.

    Drug discovery.

    Quinn Karylle Fuentes · 87問 · 2年前

    Drug discovery.

    Drug discovery.

    87問 • 2年前
    Quinn Karylle Fuentes

    disease of lipids.

    disease of lipids.

    Quinn Karylle Fuentes · 13問 · 2年前

    disease of lipids.

    disease of lipids.

    13問 • 2年前
    Quinn Karylle Fuentes

    Intro (identify structure)

    Intro (identify structure)

    Quinn Karylle Fuentes · 57問 · 2年前

    Intro (identify structure)

    Intro (identify structure)

    57問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 98問 · 2年前

    Carbohydrates

    Carbohydrates

    98問 • 2年前
    Quinn Karylle Fuentes

    Dynamic.

    Dynamic.

    Quinn Karylle Fuentes · 96問 · 2年前

    Dynamic.

    Dynamic.

    96問 • 2年前
    Quinn Karylle Fuentes

    Unit 1

    Unit 1

    Quinn Karylle Fuentes · 32問 · 2年前

    Unit 1

    Unit 1

    32問 • 2年前
    Quinn Karylle Fuentes

    問題一覧

  • 1

    The study of the chemical and physical properties of drugs, their components, and their activities in living organisms.

    Biopharmaceuticals.

  • 2

    The science that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption.

    Biopharmaceuticals

  • 3

    measurement of the rate and extent of systemic absorption of therapeutically active drug

    Bioavailability

  • 4

    The study of the time course of drug movement in the body during absorption, distribution, and elimination.

    Pharmacokinetics.

  • 5

    The study of the relationships between drug dosage regimens and concentration–time profiles

    Clinical pharmacokinetics.

  • 6

    Application of pharmacokinetic methods to drug therapy.

    Clinical pharmacokinetics

  • 7

    volume of fluid completely cleared of drug per unit time

    Clearance.

  • 8

    distributed to produce the measured concentration

    Volume of distribution

  • 9

    time taken for 50% of the drug to be eliminated

    Elimination half life

  • 10

    Study of pharmacokinetics differences of drugs in various population

    Population pharmacokinetics

  • 11

    Employed for very potent drug to optimize efficacy and to prevent any adverse toxicity

    Therapeutic drug monitoring.

  • 12

    Provides pharmacokinetic and drug analysis services for safe drug monitoring

    Clinical pharmacokinetics service.

  • 13

    Development of biologic sampling techniques, analytical methods for the measurement of drugs and metabolites and procedure that facilitates data collection and manipulation

    Expirinental pharmacokinetics.

  • 14

    Development of pharmacokinetics models that predict drug disposition after administration

    Theoretical pharmacokinetics.

  • 15

    involves human subjects/ laboratory animals

    In VIVO

  • 16

    employs test apparatus and equipment without involving human subjects/ laboratory animals

    in VITRO

  • 17

    hypothesis using mathematical terms to describe quantitative relationship concisely.

    Model

  • 18

    The study of the relation of the drug concentration or amount at the site of action and its pharmacologic response

    Pharmacodynamic

  • 19

    The study of the adverse effects of drugs and toxic substances in the body

    Clinical toxicology.

  • 20

    description of drug distribution and elimination

    Drug disposition

  • 21

    refers to the dose and various measure of acute or integrated drug concentrations in plasma and other biological fluid

    Drug exposure.

  • 22

    refers to the direct measure of the pharmacologic effect of the drug

    Drug response.

  • 23

    The rate at which the solid drug enters into solution is often the rate limiting step in bioavailability.

    Drug dissolution.

  • 24

    What equation describes the diffusion controlled rate of drug dissolution

    Noyes-Whitney equation

  • 25

    in a saturated solution is a static (equilibrium) property. The dissolution rate of a drug is a dynamic property related to the rate of absorption.

    Drug solubility

  • 26

    The partition coefficient of a drug is the ratio of the solubility of the drug, at equilibrium, in a non-aqueous solvent

    Partition coefficient

  • 27

    Drugs that are weak electrolytes (acids or bases) exist in both an ionized form and a nonionized form in solution

    Extent of ionization

  • 28

    The extent of ionization depends on the pKa of the weak electrolyte and the pH of the solution (£T/F)

    True

  • 29

    This equation describes the relation between the ionized and the nonionized forms of a drug as a function of pH and pKa

    Henderson-Hasselbalch equation

  • 30

    The choice of salt form for a drug depends on the desired physical , chemical , or pharmacologic properties.

    Salt formation.

  • 31

    the ability of a drug to exist in more than one crystalline form Amorphous, or noncrystalline, forms of a drug have faster dissolution rates than do crystalline forms.

    Polymorphism.

  • 32

    The ability of a drug to exist as optically active stereoisomers or enantiomers

    Chirality

  • 33

    Individual enantiomers may not have the same pharmacokinetic and pharmacodynamic activity.

    Chirality.

  • 34

    Drugs may exist in a hydrated, or solvated, form or as an anhydrous molecule Dissolution rates differ for hydrated and anhydrous forms.

    Hydrates

  • 35

    Decrease water solubility

    Hydrates

  • 36

    formed by the reversible or irreversible association of two or more interacting molecules or ions.

    Complex formation.

  • 37

    are complexes that typically involve a ring-like structure formed by the interaction between a partial ring of atoms and a metal Ex. hemoglobin, insulin, cyanocobalamin

    Chelates

  • 38

    Complex formation usually alters the physical and chemical characteristics of the drug

    Chelates

  • 39

    the process with the slowest rate constant in a system of simultaneous kinetic processes.

    Rate limiting step

  • 40

    delivery of the active ingredient from a dosage form into solution.

    Liberation

  • 41

    the first step which determines onset of action, rate of absorption, availability, etc., which is true for all drug products by all routes of administration

    Liberation

  • 42

    The process of uptake of the compound from the site of administration into the systemic circulation.

    Absorption

  • 43

    The movement of the drug from the site of application to the bloodstream.

    Absorption

  • 44

    transfer of the drug from the blood to extravascular fluids and tissues

    Distribution

  • 45

    The amount of blood perfusion in an area of the body also affects the rate at which the drug could be distributed there.

    Distribution

  • 46

    Estimate the extent of drug distribution in the body

    Volume of distribution

  • 47

    Relates the plasma conc to the amount of drug

    Volume of distribution

  • 48

    Detoxification/Biotransformation enzymatic or biochemical transformation of the drug substance to (usually less toxic) metabolic products, which may be eliminated more readily from the body

    Metabolism

  • 49

    final loss of the drug substance or its metabolites from the body

    Excretion.

  • 50

    Make the drug MORE POLAR

    Metabolism